Latest Insights

Novartis Expands Radiopharmaceutical Portfolio with $745M Deal with Ratio Therapeutics

Novartis has struck a licensing agreement with Boston-based biotech Ratio Therapeutics, securing global rights to a promising cancer candidate targeting somatostatin receptor 2 (SSTR2). The deal, announced on November 18, …

Continue ›››

Medable Adds Generative AI to Simplify and Speed Up Clinical Trials

Medable Inc. has introduced generative AI capabilities to its Medable Studio platform to streamline and accelerate digital and decentralized clinical trial workflows. The new feature, called Medable AI, simplifies study …

Continue ›››

40,000 NHS Healthcare Workers to Get AI Tool That Cuts Admin Time by 80%

A new partnership between Corti and BigHand will bring a specialized AI tool to 40,000 healthcare workers across 76 NHS trusts. The tool is designed to reduce administrative work by …

Continue ›››

Survey Highlights Critical Need for AI Adoption in Regulatory Affairs Amid Unsustainable Workloads

New research commissioned by ArisGlobal, a provider of life sciences technology solutions, reveals that surging regulatory workloads are forcing life sciences companies to prioritize advanced AI adoption in regulatory affairs …

Continue ›››

What will be the key trends in AI innovation in the Pharmaceutical Industry in 2025?

The pharmaceutical industry is undergoing transformation thanks to artificial intelligence (AI) in particular GenAI. From drug discovery and manufacturing to speeding up clinical trials and improving sales force effectiveness, AI …

Continue ›››

Immunai and Teva Collaborate to Advance Clinical Trials in Oncology and Immunology

Immunai, an AI-driven biotech company focused on mapping the human immune system, has partnered with Teva Pharmaceuticals in a multi-year collaboration aimed at improving clinical trial outcomes for oncology and …

Continue ›››

Enveda Advances AI-Discovered, Nature-Derived Drug ENV-294 to Phase 1 Trials

Enveda, a biotechnology company transforming nature’s chemistry into medicines using AI, has announced the FDA clearance of an investigational new drug (IND) application for ENV-294. This first-in-class small molecule, designed …

Continue ›››

Genesis Therapeutics Collaborates with NVIDIA and Secures Additional NVentures Funding to Accelerate AI-Driven Drug Discovery

Genesis Therapeutics has announced a collaboration with NVIDIA to advance its AI platform, GEMS (Genesis Exploration of Molecular Space). The partnership is bolstered by an additional equity investment from NVentures, …

Continue ›››

Novartis Expands Radiopharmaceutical Portfolio with $745M Deal with Ratio Therapeutics

Medable Adds Generative AI to Simplify and Speed Up Clinical Trials

40,000 NHS Healthcare Workers to Get AI Tool That Cuts Admin Time by 80%

Survey Highlights Critical Need for AI Adoption in Regulatory Affairs Amid Unsustainable Workloads

What will be the key trends in AI innovation in the Pharmaceutical Industry in 2025?

Immunai and Teva Collaborate to Advance Clinical Trials in Oncology and Immunology

Enveda Advances AI-Discovered, Nature-Derived Drug ENV-294 to Phase 1 Trials

Genesis Therapeutics Collaborates with NVIDIA and Secures Additional NVentures Funding to Accelerate AI-Driven Drug Discovery

Recursion Unveils OpenPhenom-S/16: A Foundation Model for Microscopy Data

Schrödinger and Novartis Forge Partnership to Scale Computational Drug Discovery

Recursion Unveils New Foundation Model for Molecular Property Prediction

AI-Driven Drug Shows Promising Phase IIa Results in Treating Fatal Lung Disease